{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:16:15Z","timestamp":1781237775881,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:00:00Z","timestamp":1695513600000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.08.019","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T05:09:59Z","timestamp":1663996199000},"page":"246-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1038-0452","authenticated-orcid":false,"given":"Samuel","family":"Vic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-1603","authenticated-orcid":false,"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.08.019_bib1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.019_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbmt.2008.09.008","article-title":"Influence of age and histology on outcome in adult non-hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the center for international blood & marrow transplant Research (CIBMTR)","volume":"14","author":"Lazarus","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib3","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.08.019_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.019_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.019_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.08.019_bib7","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.019_bib8","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.08.019_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","author":"Friedberg","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.ejca.2022.08.019_bib10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","article-title":"Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry","volume":"93","author":"Jantunen","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2022.08.019_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bjh.13561","article-title":"Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma","volume":"171","author":"Gohil","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.08.019_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2019.09.007","article-title":"Evaluation of the impact of autologous hematopoietic stem cell transplantation on the quality of life of older patients with lymphoma","volume":"26","author":"Lemieux","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2019.01.002","article-title":"Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease","volume":"79","author":"Lemieux","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2022.08.019_bib14","first-page":"4184","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2022.08.019_bib15","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.bbmt.2019.09.012","article-title":"Conditional long-term survival after autologous hematopoietic cell transplantation for diffuse large B cell lymphoma","volume":"25","author":"El-Asmar","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European blood and marrow transplantation registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","volume":"55","author":"Gonz\u00e1lez-Barca","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2010.1.237","article-title":"Comorbidities and hematopoietic cell transplantation outcomes","author":"Sorror","year":"2010","journal-title":"Hematology"},{"key":"10.1016\/j.ejca.2022.08.019_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","article-title":"Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant Research study","volume":"21","author":"Sorror","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.616.616","article-title":"Comorbidity, lactate dehydrogenase (LDH), and chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib21","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic cell transplantation\u2013specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib22","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2008.05.002","article-title":"Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-hodgkin lymphoma","volume":"14","author":"Wildes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib23","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.08.019_bib24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy \u2013 a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2022.08.019_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/bmt.2017.192","article-title":"Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?","volume":"53","author":"Hegde","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.6004\/jnccn.2014.0009","article-title":"Senior adult oncology, version 2.2014","volume":"12","author":"Hurria","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejca.2022.08.019_bib28","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2022.08.019_bib29","unstructured":"Holmberg, L. A., Deeg, H. J. & Sandmaier, B. M. Determining eligibility for autologous hematopoietic cell transplantation. vol. 28."},{"key":"10.1016\/j.ejca.2022.08.019_bib30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41409-018-0265-7","article-title":"Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables","volume":"54","author":"Tay","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET\u2013driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib36","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib37","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib38","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2022.08.019_bib39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.22911","article-title":"The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation","volume":"110","author":"Filmont","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.08.019_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy: pre-Transplant PET for Relapsed Lymphoma","author":"Dickinson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.08.019_bib41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.08.019_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.08.019_bib43","first-page":"3119","article-title":"Standard-of-Care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2022.08.019_bib44","first-page":"3095","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2022.08.019_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149679","article-title":"Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL): impact of age and specific organ dysfunction","volume":"138","author":"Locke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib46","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejca.2022.08.019_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146397","volume":"138","author":"Landsburg","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib48","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2022.08.019_bib49","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26330","article-title":"Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel","volume":"96","author":"Wudhikarn","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2022.08.019_bib51","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejca.2022.08.019_bib52","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejca.2022.08.019_bib53","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejca.2022.08.019_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed\/refractory large B-cell lymphoma","author":"Rejeski","year":"2021","journal-title":"Blood blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150721","article-title":"A propensity score-matched comparison of axi-cel and tisa-cel for relapsed\/refractory diffuse large B-cell lymphoma in real-life: a lysa study from the descar-T registry","volume":"138","author":"Bachy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib56","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","author":"Bishop","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.019_bib57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory large B cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.08.019_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150431","article-title":"A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:59Z","timestamp":1760733539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922005068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":58,"alternative-id":["S0959804922005068"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}